Nanologica AB (publ) (NICA.ST)
SEK 0.9
(3.45%)
SEK 0.9
(3.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -62.11 Million SEK | -49.78% |
| 2022 | -38.36 Million SEK | -32.47% |
| 2021 | -31.12 Million SEK | -109.09% |
| 2020 | -13.04 Million SEK | 10.25% |
| 2019 | -14.51 Million SEK | 12.86% |
| 2018 | -18.86 Million SEK | -12.08% |
| 2017 | -15.85 Million SEK | 14.15% |
| 2016 | -18.55 Million SEK | -61.73% |
| 2015 | -11.55 Million SEK | 10.54% |
| 2014 | -13.04 Million SEK | -96.81% |
| 2013 | -6.48 Million SEK | -80.41% |
| 2012 | -3.59 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.61 Million SEK | 56.46% |
| 2024 Q2 | -7.09 Million SEK | 42.92% |
| 2023 Q1 | -7.35 Million SEK | 24.03% |
| 2023 Q3 | -6.42 Million SEK | 32.85% |
| 2023 Q2 | -9.56 Million SEK | -30.03% |
| 2023 FY | - SEK | -49.78% |
| 2023 Q4 | -26.87 Million SEK | -318.43% |
| 2022 Q3 | -6.63 Million SEK | 30.04% |
| 2022 Q2 | -9.48 Million SEK | 25.21% |
| 2022 FY | - SEK | -32.47% |
| 2022 Q1 | -12.68 Million SEK | -25.75% |
| 2022 Q4 | -9.68 Million SEK | -45.92% |
| 2021 Q1 | -4.99 Million SEK | -1829.73% |
| 2021 FY | - SEK | -109.09% |
| 2021 Q2 | -5.17 Million SEK | -3.6% |
| 2021 Q4 | -10.08 Million SEK | -14.72% |
| 2021 Q3 | -8.79 Million SEK | -69.8% |
| 2020 Q1 | -5.08 Million SEK | -0.07% |
| 2020 FY | - SEK | 10.25% |
| 2020 Q4 | -259 Thousand SEK | 94.38% |
| 2020 Q2 | -3.09 Million SEK | 39.12% |
| 2020 Q3 | -4.6 Million SEK | -48.71% |
| 2019 FY | - SEK | 12.86% |
| 2019 Q3 | -4.06 Million SEK | 0.07% |
| 2019 Q2 | -4.06 Million SEK | -78.48% |
| 2019 Q1 | -2.27 Million SEK | 53.4% |
| 2019 Q4 | -5.08 Million SEK | -25.23% |
| 2018 Q1 | -3.94 Million SEK | -513.78% |
| 2018 Q2 | -4.82 Million SEK | -22.32% |
| 2018 Q3 | -4.11 Million SEK | 14.64% |
| 2018 Q4 | -4.88 Million SEK | -18.71% |
| 2018 FY | - SEK | -12.08% |
| 2017 Q2 | -5.76 Million SEK | 1.05% |
| 2017 FY | - SEK | 14.15% |
| 2017 Q4 | -642.25 Thousand SEK | 82.63% |
| 2017 Q3 | -3.69 Million SEK | 35.83% |
| 2017 Q1 | -5.82 Million SEK | -97.87% |
| 2016 Q1 | -4.8 Million SEK | -19.67% |
| 2016 FY | - SEK | -61.73% |
| 2016 Q4 | -2.94 Million SEK | 44.85% |
| 2016 Q3 | -5.33 Million SEK | 2.45% |
| 2016 Q2 | -5.46 Million SEK | -13.77% |
| 2015 Q4 | -4.01 Million SEK | -8.45% |
| 2015 Q1 | -869 Thousand SEK | 79.47% |
| 2015 Q2 | -2.92 Million SEK | -236.71% |
| 2015 FY | - SEK | 10.54% |
| 2015 Q3 | -3.7 Million SEK | -26.59% |
| 2014 Q4 | -4.23 Million SEK | 0.0% |
| 2014 Q2 | -2.2 Million SEK | 0.0% |
| 2014 Q1 | -2.2 Million SEK | 0.0% |
| 2014 FY | - SEK | -96.81% |
| 2014 Q3 | -4.23 Million SEK | -91.7% |
| 2013 FY | - SEK | -80.41% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | -41.543% |
| Amniotics AB (publ) | -27.14 Million SEK | -128.858% |
| BioArctic AB (publ) | 275.38 Million SEK | 122.557% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 83.111% |
| Camurus AB (publ) | 562.54 Million SEK | 111.042% |
| Cantargia AB (publ) | -284.31 Million SEK | 78.151% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -217.274% |
| CombiGene AB (publ) | -35.33 Million SEK | -75.795% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 55.897% |
| Genovis AB (publ.) | 64.57 Million SEK | 196.201% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 45.94% |
| Mendus AB (publ) | -97.84 Million SEK | 36.514% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -67.78% |
| Intervacc AB (publ) | -68.98 Million SEK | 9.946% |
| Kancera AB (publ) | -61.88 Million SEK | -0.372% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -131.934% |
| LIDDS AB (publ) | -39.67 Million SEK | -56.589% |
| Lipum AB (publ) | -37.11 Million SEK | -67.351% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -413.211% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 297.806% |
| NextCell Pharma AB | -40.98 Million SEK | -51.565% |
| OncoZenge AB (publ) | 7.26 Million SEK | 954.927% |
| Saniona AB (publ) | -69.69 Million SEK | 10.87% |
| Simris Alg AB (publ) | -22.36 Million SEK | -177.776% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 80.433% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 77.975% |
| Xintela AB (publ) | -53.47 Million SEK | -16.173% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 63.42% |
| Ziccum AB (publ) | -20.34 Million SEK | -205.373% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -336.935% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -263.598% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 3106050.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 73.857% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2886.49% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -362.505% |
| Corline Biomedical AB | -1.69 Million SEK | -3573.507% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 64.16% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -13.343% |
| Aptahem AB (publ) | -10 Million SEK | -520.617% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 637.873% |
| Fluicell AB (publ) | -25.91 Million SEK | -139.712% |
| Biovica International AB (publ) | -119.5 Million SEK | 48.02% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -47.118% |
| AcouSort AB (publ) | -16.7 Million SEK | -271.903% |
| Abliva AB (publ) | -93.6 Million SEK | 33.639% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 80.533% |
| 2cureX AB (publ) | -35.13 Million SEK | -76.796% |
| I-Tech AB | 30.34 Million SEK | 304.709% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 91.307% |
| Cyxone AB (publ) | -20.41 Million SEK | -204.296% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 39.368% |
| Biosergen AB | 228 Thousand SEK | 27345.175% |
| SynAct Pharma AB | -222.7 Million SEK | 72.107% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -41.627% |
| BioInvent International AB (publ) | -312.7 Million SEK | 80.135% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 20176.403% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 148005.903% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 73.181% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -604.898% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 42.778% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -441.625% |